Zydus Cadila gets USFDA nod for Mycophenolate Mofetil
New Delhi: Cadila Healthcare said its group firm Zydus Cadila has received final approval from the USFDA to market Mycophenolate mofetil for injection used in organ transplants to prevent rejection.
The approval is for Mycophenolate Mofetil injection of strength 500mg/vial, the company said in a BSE filing.
The drug is indicated for use in combination with other drugs -- cyclosporine and corticosteroids for prophylaxis of organ rejection in patients receiving kidney, liver or heart transplants, it added.
It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad, the company said.
The group now has more than 140 approvals and has so far filed over 300 ANDAs, the filing said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd